Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 452 of the 452 references it cites were found in a registry or an index; 480 of the 632 sources its claims cite were checked for support.

Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery

Open access
Tanaka, Masaru · 2026 · Biomedicines

Abstract

Major depressive disorder remains a leading cause of disability, and decades of monoamine-centered pharmacology have yielded delayed and often incomplete relief. Rapid-acting antidepressants reshaped the field by linking swift symptom improvement to glutamatergic plasticity, yet durable benefit depends on how newly reconfigured circuits are stabilized and tuned. This review synthesizes evidence that antidepressant efficacy arises from the coordinated engagement of synaptic plasticity, spanning induction and consolidation, and intrinsic excitability, which provides gain control, and proposes an integrated framework to guide future discovery. It first outlines induction through N-methyl-D-aspartate receptors (NMDARs) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), exemplified by ketamine and esketamine, followed by consolidation mediated by tropomyosin receptor kinase B (TrkB) signaling, translational disinhibition via eukaryotic elongation factor 2 kinase (eEF2K), and presynaptic stabilization indexed by synaptic vesicle glycoprotein 2A (SV2A); together, these processes transform transient potentiation into persistent network change. It then highlights intrinsic excitability, emphasizing voltage-gated potassium channel subfamily Q (Kv7), hyperpolarization-activated cyclic nucleotide-gated (HCN), and G protein-gated inwardly rectifying potassium (GIRK) channels as circuit-level governors that normalize firing and limit relapse-prone hyperexcitability. Finally, it presents the Induction–Consolidation–Maintenance (ICM) framework as a hypothesis-generating roadmap for future studies, with SV2A positron emission tomography (PET), electroencephalography (EEG), and functional magnetic resonance imaging (fMRI) biomarkers discussed as candidate tools rather than validated guides for treatment timing or patient selection. The proposed contribution is not another list of plasticity pathways, but a phase-specific model that links synaptic induction, consolidation, and excitability-based maintenance to distinct therapeutic windows, biomarkers, and relapse-prevention strategies.

Overview

CoChat Summary

TL;DR

This narrative review proposes the Induction–Consolidation–Maintenance (ICM) framework, which treats antidepressant response as a temporally ordered process in which glutamatergic synaptic plasticity is induced, consolidated, and then stabilized by intrinsic excitability tuning. It argues that durable remission requires pairing plasticity inducers (e.g., ketamine/esketamine) with consolidation and maintenance mechanisms (TrkB, eEF2K, SV2A) and ion-channel–based gain control (Kv7, HCN, GIRK).

Key findings

  • Antidepressant action is reframed as three mechanistically distinct phases: induction via NMDAR/AMPAR glutamatergic signaling (ketamine, esketamine, DXM-bupropion), consolidation via TrkB signaling, eEF2K-mediated translational disinhibition, and presynaptic stabilization indexed by SV2A, and maintenance via intrinsic excitability.
  • Rapid glutamatergic strategies reliably produce rapid relief but responses "frequently decay within days to weeks, with high relapse rates following discontinuation"; maintenance regimens only partially offset this erosion.
  • Intrinsic excitability channels are positioned as the maintenance layer: Kv7 (M-current) openers dampen hyperexcitability and show the strongest clinical signal (ezogabine reduced depressive symptoms and improved reward sensitivity in MDD with anhedonia, but pigmentation/urinary liabilities limited use), whereas HCN and GIRK strategies remain "largely mechanistic or preclinical."
  • Translational failures are treated as boundary conditions: rapastinel failed to meet primary endpoints in three pivotal phase 3 adjunctive MDD trials, and no clinical-grade eEF2K inhibitor exists; TrkB agonists face reproducibility and target-specificity concerns.

Methods

  • Narrative review synthesizing heterogeneous preclinical and clinical evidence; the author states the ICM framework "is used to organize heterogeneous evidence rather than to rank mechanisms by clinical readiness."
  • Ketamine is treated as the best-established clinical entry point into rapid plasticity, with non-ketamine pathways discussed "according to their current evidentiary maturity."
  • No systematic search strategy, inclusion criteria, or quantitative synthesis is reported; the paper is organized into sections on induction/consolidation, presynaptic and network integrity (SV2A), intrinsic excitability (Kv7, HCN, GIRK), combinatorial strategies, and future directions.

Limitations

  • Stated: the ICM framework is "a narrative synthesis rather than a validated clinical algorithm"; biomarkers (SV2A PET, MRS, EEG, fMRI, actigraphy) "are not yet validated tools for routine patient stratification"; and TrkB modulators, eEF2K inhibitors, SV2A enhancers, and ion-channel strategies remain at earlier stages of translation than ketamine/esketamine.
  • Stated: long-term modulation of plasticity pathways may stabilize maladaptive circuits, alter excitation–inhibition balance, or change seizure thresholds; concerns include off-target signaling, abuse liability, and uncertainty about chronic ketamine/esketamine exposure.
  • Evident from the text: the review is single-authored and non-systematic, with no stated search protocol or evidence-grading method, so the relative weighting of mechanisms reflects the author's narrative judgment; the author also notes that figures and tables "should be read as organizing tools... not as evidence that all pathways or targets are equally validated."

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/biomedicines14061265

Cites

452 of 452 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Plasticity window and consolidation timeline in rapid antidepressant action. Rapid-acting antidepressant effects can be framed as a staged transition from induction to consolidation. During induction, NMDAR antagonism, often through interneuron disinhibition, increases glutamate release and AMPAR throughput, opening a brief plasticity window over minutes to hours. Early BDNF release and mTORC1 activation support synaptic remodeling and dendritic spine formation, but these changes remain labile. Durable benefit requires consolidation over hours to days, during which TrkB signaling stabilizes potentiated synapses, eEF2K inhibition sustains local protein synthesis, and SV2A supports presynaptic vesicle cycling. The key concept is timing: adjunctive interventions may be most effective when aligned with the consolidation phase. AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; BDNF, brain-derived neurotrophic factor; eEF2K, eukaryotic elongation factor 2 kinase; mTORC1, mechanistic target of rapamycin complex 1; NMDAR, N-methyl-D-aspartate receptor; SV2A, synaptic vesicle glycoprotein 2A; TrkB, tropomyosin receptor kinase B.
Figure 1 Plasticity window and consolidation timeline in rapid antidepressant action. Rapid-acting antidepressant effects can be framed as a staged transition from induction to consolidation. During induction, NMDAR antagonism, often through interneuron disinhibition, increases glutamate release and AMPAR throughput, opening a brief plasticity window over minutes to hours. Early BDNF release and mTORC1 activation support synaptic remodeling and dendritic spine formation, but these changes remain labile. Durable benefit requires consolidation over hours to days, during which TrkB signaling stabilizes potentiated synapses, eEF2K inhibition sustains local protein synthesis, and SV2A supports presynaptic vesicle cycling. The key concept is timing: adjunctive interventions may be most effective when aligned with the consolidation phase. AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; BDNF, brain-derived neurotrophic factor; eEF2K, eukaryotic elongation factor 2 kinase; mTORC1, mechanistic target of rapamycin complex 1; NMDAR, N-methyl-D-aspartate receptor; SV2A, synaptic vesicle glycoprotein 2A; TrkB, tropomyosin receptor kinase B.CC BY · PubMed Central
Figure 2 Synapse-to-spike targets for plasticity consolidation and gain control. This schematic maps key antidepressant-relevant targets onto a cortical pyramidal neuron. At dendritic spines, TrkB supports consolidation by linking transient potentiation to stable spine maturation, while eEF2K acts as a local translation checkpoint that regulates protein synthesis needed for synaptic persistence. At presynaptic boutons, SV2A stabilizes vesicle cycling and release fidelity, providing a bridge between synaptogenic induction and maintenance of neurotransmission. Across the soma and dendrites, Kv7, HCN, and GIRK channels regulate intrinsic excitability by tuning firing threshold, dendritic integration, resonance, and inhibitory tone. Together, these targets illustrate how antidepressant discovery can coordinate synaptic remodeling with circuit-level gain control. eEF2K, eukaryotic elongation factor 2 kinase; GIRK, G protein-gated inwardly rectifying potassium channel; HCN, hyperpolarization-activated cyclic nucleotide-gated channel; Kv7, voltage-gated potassium channel subfamily Q; SV2A, synaptic vesicle glycoprotein 2A; TrkB, tropomyosin receptor kinase B.
Figure 2 Synapse-to-spike targets for plasticity consolidation and gain control. This schematic maps key antidepressant-relevant targets onto a cortical pyramidal neuron. At dendritic spines, TrkB supports consolidation by linking transient potentiation to stable spine maturation, while eEF2K acts as a local translation checkpoint that regulates protein synthesis needed for synaptic persistence. At presynaptic boutons, SV2A stabilizes vesicle cycling and release fidelity, providing a bridge between synaptogenic induction and maintenance of neurotransmission. Across the soma and dendrites, Kv7, HCN, and GIRK channels regulate intrinsic excitability by tuning firing threshold, dendritic integration, resonance, and inhibitory tone. Together, these targets illustrate how antidepressant discovery can coordinate synaptic remodeling with circuit-level gain control. eEF2K, eukaryotic elongation factor 2 kinase; GIRK, G protein-gated inwardly rectifying potassium channel; HCN, hyperpolarization-activated cyclic nucleotide-gated channel; Kv7, voltage-gated potassium channel subfamily Q; SV2A, synaptic vesicle glycoprotein 2A; TrkB, tropomyosin receptor kinase B.CC BY · PubMed Central
Figure 3 Phase-timed combination strategies to stabilize antidepressant circuit remodeling. This schematic summarizes a staged strategy for converting rapid symptom relief into durable remission. Plasticity inducers such as ketamine or DXM-bupropion open a transient plasticity window during which maladaptive circuit states are most modifiable. Within and shortly after this period, consolidation-focused interventions, including TrkB modulation, eEF2K inhibition, and SV2A enhancement, are positioned to stabilize synaptic strengthening and preserve presynaptic reliability. In parallel, intrinsic excitability modulators targeting Kv7, HCN, and GIRK channels provide gain control, constrain hyperexcitability, and support adaptive oscillatory dynamics. Neuromodulatory and behavioral interventions are depicted as most effective when aligned with this window, thereby reinforcing circuit rewiring and prolonging remission. DXM, dextromethorphan; eEF2K, eukaryotic elongation factor 2 kinase; GIRK, G protein-gated inwardly rectifying potassium channel; HCN, hyperpolarization-activated cyclic nucleotide-gated channel; iTBS, intermittent theta-burst stimulation; Kv7, voltage-gated potassium channel subfamily Q; SV2A, synaptic vesicle glycoprotein 2A; TrkB, tropomyosin receptor kinase B.
Figure 3 Phase-timed combination strategies to stabilize antidepressant circuit remodeling. This schematic summarizes a staged strategy for converting rapid symptom relief into durable remission. Plasticity inducers such as ketamine or DXM-bupropion open a transient plasticity window during which maladaptive circuit states are most modifiable. Within and shortly after this period, consolidation-focused interventions, including TrkB modulation, eEF2K inhibition, and SV2A enhancement, are positioned to stabilize synaptic strengthening and preserve presynaptic reliability. In parallel, intrinsic excitability modulators targeting Kv7, HCN, and GIRK channels provide gain control, constrain hyperexcitability, and support adaptive oscillatory dynamics. Neuromodulatory and behavioral interventions are depicted as most effective when aligned with this window, thereby reinforcing circuit rewiring and prolonging remission. DXM, dextromethorphan; eEF2K, eukaryotic elongation factor 2 kinase; GIRK, G protein-gated inwardly rectifying potassium channel; HCN, hyperpolarization-activated cyclic nucleotide-gated channel; iTBS, intermittent theta-burst stimulation; Kv7, voltage-gated potassium channel subfamily Q; SV2A, synaptic vesicle glycoprotein 2A; TrkB, tropomyosin receptor kinase B.CC BY · PubMed Central
Figure 4 Biotype-guided treatment roadmap for precision antidepressant targeting. The schematic links clinical screening phenotypes—anhedonia, rumination, and agitation/sleep disruption—to biomarker-informed stratification using EEG slope, rACC activity, DMN/PFC coupling, SV2A PET, and sleep/actigraphy readouts. These profiles guide target matching toward TrkB/SV2A-based plasticity support, HCN modulation, or GIRK/Kv7-directed gain control, illustrating how biomarker-guided selection may enable rational, biotype-aligned antidepressant interventions. DMN, default mode network; EEG, electroencephalography; GIRK, G protein-gated inwardly rectifying potassium channel; HCN, hyperpolarization-activated cyclic nucleotide-gated channel; Kv7, voltage-gated potassium channel subfamily Q; PET, positron emission tomography; PFC, prefrontal cortex; rACC, rostral anterior cingulate cortex; SV2A, synaptic vesicle glycoprotein 2A; TrkB, tropomyosin receptor kinase B.
Figure 4 Biotype-guided treatment roadmap for precision antidepressant targeting. The schematic links clinical screening phenotypes—anhedonia, rumination, and agitation/sleep disruption—to biomarker-informed stratification using EEG slope, rACC activity, DMN/PFC coupling, SV2A PET, and sleep/actigraphy readouts. These profiles guide target matching toward TrkB/SV2A-based plasticity support, HCN modulation, or GIRK/Kv7-directed gain control, illustrating how biomarker-guided selection may enable rational, biotype-aligned antidepressant interventions. DMN, default mode network; EEG, electroencephalography; GIRK, G protein-gated inwardly rectifying potassium channel; HCN, hyperpolarization-activated cyclic nucleotide-gated channel; Kv7, voltage-gated potassium channel subfamily Q; PET, positron emission tomography; PFC, prefrontal cortex; rACC, rostral anterior cingulate cortex; SV2A, synaptic vesicle glycoprotein 2A; TrkB, tropomyosin receptor kinase B.CC BY · PubMed Central

Verification

Claims the paper makes

189 Valid · 51 Not valid · 24 Not checked · 56 Own results and interpretations

89 more claims · 66 with their cited sources checked

Create a free account to see all 320 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 211
  • Probably not a substantial claim. 41
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 431 references

Metadata

Authors
Tanaka, M.
Affiliations
University of Szeged (HU)
Corresponding author
Tanaka, Masaru
Venue
Biomedicines
Publisher
MDPI AG
Published
2026-06-01
Volume
14
Issue
6
Pages
1265
ISSN
2227-9059 (ISSN-L)
OpenAlex
W7163031031
Cited by
0
References
431
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
synaptic plasticity, intrinsic excitability, major depressive disorder, rapid-acting antidepressants, NMDA receptor, AMPA receptors, ketamine, esketamine, TrkB signaling, eEF2K, SV2A, Kv7 channels, HCN channels, GIRK channels, gain control, hyperexcitability, relapse prevention, PET biomarkers, EEG biomarkers, fMRI biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery. https://app.cochat.ai/papers/10.3390/biomedicines14061265
The paper
Tanaka, M. (2026). Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery. Biomedicines. https://doi.org/10.3390/biomedicines14061265

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.